PURPOSE:
Early diagnosis of cancer and leukemia. Differential diagnosis of tumors. Detection of metastases. Assessment of immunological status. TMF monitoring. Monitoring the effectiveness of the treatment of patients.
DESCRIPTION:
Kits of purified monoclonal antibodies (mAbs) produced by hybridomas. The collection of hybridomas includes clitin-producers of MCAT to CD3, CD4, CD7, CD8, CD10, CD13, CD15, CD16, CD20, CD22, CD25, CD27, CD34, CD37, CD38, CD43, CD45, CD45RA, CD48, CD54, CD56, CD66e , CD95, CD150, CD227, CD326, HLA-ABC, HLA-DR, kappa and lambda of light chains of immunoglobulins, pan-cytokeratin, cytokeratin-18, p53 and IPO-38. The development is included in the State Register of Medical Products and is allowed for use in Ukraine (perpetual license); on order, manufacturing, cleaning, checking the specificity, delivery and quality assurance of the ICAT, personnel training are carried out.
ADVANTAGES:
There are no domestic analogues of the development.
TECHNICAL AND ECONOMIC EFFECT:
In terms of specificity and quality, domestic MKATs are not inferior to foreign counterparts at a significantly lower cost.
RECOMMENDED FIELD OF APPLICATION:
Medicine. Diagnosis of cancer and leukemia.
RESULTS OF THE RESEARCH:
Ready for implementation.
STAGE OF THE DEVELOPMENT READINESS:
Ready for implementation.
TRANSFER OPPORTUNITY:
-
- Joint production, sale, operation.
- Creation of a joint venture.
NOVELTY:
1 patent of Ukraine.
IF YOU ARE INTERESTED IN THIS DEVELOPMENT, PLEASE,
WRITE TO US